Publications | BMT CTN

BMT CTN investigators have published >135 manuscripts, including >30 primary study results papers, in numerous peer-reviewed journals, including the New England Journal of Medicine, Journal of Clinical Oncology, and Blood. Selected publications are summarized for dissemination to patients and the lay public.

Note: To find a complete list of Publications, please see listing here.

Found 18 results

Filters: Author is Levine, John E [Clear All Filters]

2022

T. - P. Lai, Verhulst, S., Dagnall, C. L., Hutchinson, A., Spellman, S. R., Howard, A., Katki, H. A., Levine, J. E., Saber, W., Aviv, A., and Gadalla, S. M., “Decoupling blood telomere length from age in recipients of allogeneic hematopoietic cell transplant in the BMT-CTN 1202.”, Front Immunol, vol. 13, p. 966301, 2022.

S. Putta, Young, B. A., Levine, J. E., Reshef, R., Nakamura, R., Strouse, C., Perales, M. - A., Howard, A., Pine, P., Shi, J., Zhang, P., Ho, V. T., and Saber, W., “Prognostic Biomarkers for Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome in Myeloablative Allogeneic Hematopoietic Cell Transplantation: Results from the Blood and Marrow Transplant Clinical Trials Network 1202 Study.”, Transplant Cell Ther, vol. 29, no. 3, pp. 166.e1-166.e10, 2022.

2021

R. Reshef, Saber, W., Bolaños-Meade, J., Chen, G., Bin Chen, Y. -, Ho, V. T., Ponce, D. M., Nakamura, R., Martens, M. J., Hansen, J. A., and Levine, J. E., “Acute GVHD Diagnosis and Adjudication in a Multicenter Trial: A Report From the BMT CTN 1202 Biorepository Study.”, J Clin Oncol, vol. 39, no. 17, pp. 1878-1887, 2021.

H. E. Heslop, Stadtmauer, E. A., Levine, J. E., Ballen, K. K., Bin Chen, Y. -, DeZern, A. E., Eapen, M., Hamadani, M., Hamilton, B. K., Hari, P., Jones, R. J., Logan, B. R., Kean, L. S., Leifer, E. S., Locke, F. L., Maziarz, R. T., Nemecek, E. R., Pasquini, M., Phelan, R., Riches, M. L., Shaw, B. E., Walters, M. C., Foley, A., Devine, S. M., and Horowitz, M. M., “Blood and Marrow Transplant Clinical Trials Network State of the Science Symposium 2021: Looking Forward as the Network Celebrates its 20th Year.”, Transplant Cell Ther, vol. 27, no. 11, pp. 885-907, 2021.

G. Meyers, Hamadani, M., Martens, M., Ali, H., Choe, H., Dawson, P., Harris, A. C., van Hooren, E., Klaassen, W., Leifer, E., MacMillan, M. L., van Oosterhout, Y., Perez, L., Pusic, I., Vo, P., and Levine, J. E., “Lessons learned from early closure of a clinical trial for steroid-refractory acute GVHD.”, Bone Marrow Transplant, vol. 57, no. 2, pp. 302-303, 2021.

2020

J. E. Levine, Antin, J. H., Allen, C. E., Burroughs, L. M., Cooke, K. R., Devine, S., Heslop, H., Nakamura, R., Talano, J. An, Yanik, G., and DiFronzo, N., “Priorities for Improving Outcomes for Nonmalignant Blood Diseases: A Report from the Blood and Marrow Transplant Clinical Trials Network.”, Biol Blood Marrow Transplant, vol. 26, no. 5, pp. e94-e100, 2020.

J. Pidala, Hamadani, M., Dawson, P., Martens, M., Alousi, A. M., Jagasia, M., Efebera, Y. A., Chhabra, S., Pusic, I., Holtan, S. G., Ferrara, J. L. M., Levine, J. E., Mielcarek, M., Anasetti, C., Antin, J. H., Bolaños-Meade, J., Howard, A., Logan, B. R., Leifer, E. S., Pritchard, T. S., Horowitz, M. M., and MacMillan, M. L., “Randomized multicenter trial of sirolimus vs prednisone as initial therapy for standard-risk acute GVHD: the BMT CTN 1501 trial.”, Blood, vol. 135, no. 2, pp. 97-107, 2020.

2018

S. G. Holtan, DeFor, T. E., Panoskaltsis-Mortari, A., Khera, N., Levine, J. E., Flowers, M. E. D., Lee, S. J., Inamoto, Y., Chen, G. L., Mayer, S., Arora, M., Palmer, J., Cutler, C. S., Arai, S., Lazaryan, A., Newell, L. F., Jagasia, M. H., Pusic, I., Wood, W. A., Renteria, A. S., Yanik, G., Hogan, W. J., Hexner, E., Ayuk, F., Holler, E., Bunworasate, U., Efebera, Y. A., Ferrara, J. L. M., Pidala, J., Howard, A., Wu, J., Bolaños-Meade, J., Ho, V., Alousi, A., Blazar, B. R., Weisdorf, D. J., and MacMillan, M. L., “Amphiregulin modifies the Minnesota Acute Graft-versus-Host Disease Risk Score: results from BMT CTN 0302/0802.”, Blood Adv, vol. 2, no. 15, pp. 1882-1888, 2018.

M. C. Pasquini, Logan, B., Jones, R. J., Alousi, A. M., Appelbaum, F. R., Bolaños-Meade, J., Flowers, M. E. D., Giralt, S., Horowitz, M. M., Jacobsohn, D., Koreth, J., Levine, J. E., Luznik, L., Maziarz, R., Mendizabal, A., Pavletic, S., Perales, M. - A., Porter, D., Reshef, R., Weisdorf, D., and Antin, J. H., “Blood and Marrow Transplant Clinical Trials Network Report on the Development of Novel Endpoints and Selection of Promising Approaches for Graft-versus-Host Disease Prevention Trials.”, Biol Blood Marrow Transplant, vol. 24, no. 6, pp. 1274-1280, 2018.

2016

S. Shenoy, Eapen, M., Panepinto, J. A., Logan, B. R., Wu, J., Abraham, A., Brochstein, J., Chaudhury, S., Godder, K., Haight, A. E., Kasow, K. A., Leung, K., Andreansky, M., Bhatia, M., Dalal, J., Haines, H., Jaroscak, J., Lazarus, H. M., Levine, J. E., Krishnamurti, L., Margolis, D., Megason, G. C., Yu, L. C., Pulsipher, M. A., Gersten, I., DiFronzo, N., Horowitz, M. M., Walters, M. C., and Kamani, N., “A trial of unrelated donor marrow transplantation for children with severe sickle cell disease.”, Blood, vol. 128, no. 21, pp. 2561-2567, 2016.

2015

J. E. Levine, Braun, T. M., Harris, A. C., Holler, E., Taylor, A., Miller, H., Magenau, J., Weisdorf, D. J., Ho, V. T., Bolaños-Meade, J., Alousi, A. M., and Ferrara, J. L. M., “A prognostic score for acute graft-versus-host disease based on biomarkers: a multicentre study.”, Lancet Haematol, vol. 2, no. 1, pp. e21-9, 2015.

M. L. MacMillan, Robin, M., Harris, A. C., DeFor, T. E., Martin, P. J., Alousi, A., Ho, V. T., Bolaños-Meade, J., Ferrara, J. L. M., Jones, R., Arora, M., Blazar, B. R., Holtan, S. G., Jacobsohn, D., Pasquini, M., Socie, G., Antin, J. H., Levine, J. E., and Weisdorf, D. J., “A refined risk score for acute graft-versus-host disease that predicts response to initial therapy, survival, and transplant-related mortality.”, Biol Blood Marrow Transplant, vol. 21, no. 4, pp. 761-7, 2015.

2014

J. Bolaños-Meade, Logan, B. R., Alousi, A. M., Antin, J. H., Barowski, K., Carter, S. L., Goldstein, S. C., Hexner, E. O., Horowitz, M. M., Lee, S. J., Levine, J. E., MacMillan, M. L., Martin, P. J., Mendizabal, A. M., Nakamura, R., Pasquini, M. C., Weisdorf, D. J., Westervelt, P., and Ho, V. T., “Phase 3 clinical trial of steroids/mycophenolate mofetil vs steroids/placebo as therapy for acute GVHD: BMT CTN 0802.”, Blood, vol. 124, no. 22, pp. 3221-7; quiz 3335, 2014.

2013

J. Bolaños-Meade, Wu, J., Logan, B. R., Levine, J. E., Ho, V. T., Alousi, A. M., Weisdorf, D. J., and Luznik, L., “Lymphocyte phenotype during therapy for acute graft-versus-host disease: a brief report from BMT-CTN 0302.”, Biol Blood Marrow Transplant, vol. 19, no. 3, pp. 481-5, 2013.

2012

N. R. Kamani, Walters, M. C., Carter, S., Aquino, V., Brochstein, J. A., Chaudhury, S., Eapen, M., Freed, B. M., Grimley, M., Levine, J. E., Logan, B., Moore, T., Panepinto, J., Parikh, S., Pulsipher, M. A., Sande, J., Schultz, K. R., Spellman, S., and Shenoy, S., “Unrelated donor cord blood transplantation for children with severe sickle cell disease: results of one cohort from the phase II study from the Blood and Marrow Transplant Clinical Trials Network (BMT CTN).”, Biol Blood Marrow Transplant, vol. 18, no. 8, pp. 1265-72, 2012.

2010

J. E. Levine, Logan, B., Wu, J., Alousi, A. M., Ho, V., Bolaños-Meade, J., and Weisdorf, D., “Graft-versus-host disease treatment: predictors of survival.”, Biol Blood Marrow Transplant, vol. 16, no. 12, pp. 1693-9, 2010.

P. A. Jacobson, Huang, J., Wu, J., Kim, M., Logan, B., Alousi, A., Grimley, M., Bolaños-Meade, J., Ho, V., Levine, J. E., and Weisdorf, D., “Mycophenolate pharmacokinetics and association with response to acute graft-versus-host disease treatment from the Blood and Marrow Transplant Clinical Trials Network.”, Biol Blood Marrow Transplant, vol. 16, no. 3, pp. 421-9, 2010.

2009

A. M. Alousi, Weisdorf, D. J., Logan, B. R., Bolaños-Meade, J., Carter, S., DiFronzo, N., Pasquini, M., Goldstein, S. C., Ho, V. T., Hayes-Lattin, B., Wingard, J. R., Horowitz, M. M., and Levine, J. E., “Etanercept, mycophenolate, denileukin, or pentostatin plus corticosteroids for acute graft-versus-host disease: a randomized phase 2 trial from the Blood and Marrow Transplant Clinical Trials Network.”, Blood, vol. 114, no. 3, pp. 511-7, 2009.